Hua Yao Tang

Huayaotang (Beijing) Biotechnology is a clinical-stage biopharmaceutical company based in China that focuses on the discovery and development of innovative biologics for cancer immunotherapy. The company utilizes its proprietary protein engineering platform to design multi-functional fusion proteins and bispecific antibodies aimed at overcoming the limitations of current checkpoint inhibitors. Its lead candidate, HYT-001, is a bifunctional fusion protein targeting both PD-L1 and TGF-beta, currently undergoing Phase 1/2 clinical trials for the treatment of advanced solid tumors. Huayaotang's broader pipeline includes next-generation immunotherapies targeting the CD47 and IL-15 pathways. By integrating advanced protein design with deep biological insights, the company seeks to provide more effective therapeutic options for patients with refractory or metastatic cancers.